Do analysts prefer PRTC or OKUR?

OnKure Therapeutics has a consensus price target of $17.50, indicating a potential upside of 644.68%. Given OnKure Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe OnKure Therapeutics is more favorable than PureTech Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 OnKure Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has stronger earnings & valuation, PRTC or OKUR?

OnKure Therapeutics has lower revenue, but higher earnings than PureTech Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PureTech Health $4.66M 91.01 -$109.74M N/A N/A OnKure Therapeutics N/A N/A -$59.52M -$3.50 N/A

Is PRTC or OKUR more profitable?

PureTech Health's return on equity of 0.00% beat OnKure Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets PureTech Health N/A N/A N/A OnKure Therapeutics N/A -49.01% -45.77%

Which has better valuation & earnings, RZLT or OKUR?

Rezolute is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rezolute N/A N/A -$77.59M -$0.76 N/A OnKure Therapeutics N/A N/A -$59.52M -$3.50 N/A

Is RZLT or OKUR more profitable?

OnKure Therapeutics' return on equity of -49.01% beat Rezolute's return on equity. Company Net Margins Return on Equity Return on Assets Rezolute N/A -62.99% -57.94% OnKure Therapeutics N/A -49.01% -45.77%

Which has preferable earnings & valuation, EIKN or OKUR?

Eikon Therapeutics is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eikon Therapeutics N/A N/A -$324.25M -$4.09 N/A OnKure Therapeutics N/A N/A -$59.52M -$3.50 N/A

Is EIKN or OKUR more profitable?

Eikon Therapeutics' return on equity of 0.00% beat OnKure Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Eikon Therapeutics N/A N/A N/A OnKure Therapeutics N/A -49.01% -45.77%

Do analysts recommend OKUR or AVTE?

OnKure Therapeutics presently has a consensus price target of $17.50, indicating a potential upside of 644.68%. Given OnKure Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe OnKure Therapeutics is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OnKure Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings & valuation, OKUR or AVTE?

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OnKure Therapeutics N/A N/A -$59.52M -$3.50 N/A Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A

Is OKUR or AVTE more profitable?

OnKure Therapeutics' return on equity of -49.01% beat Aerovate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets OnKure Therapeutics N/A -49.01% -45.77% Aerovate Therapeutics N/A -90.19% -77.47%

OnKure Therapeutics (OKUR) Competitors

$2.33 -0.03 (-1.06%)

As of 11:00 AM Eastern

Compare

OKUR vs. PRTC, RZLT, ARCT, EIKN, and AVTE

Should you buy OnKure Therapeutics stock or one of its competitors? OnKure Therapeutics's main competitors and comparable companies include PureTech Health (PRTC), Rezolute (RZLT), Arcturus Therapeutics (ARCT), Eikon Therapeutics (EIKN), and Aerovate Therapeutics (AVTE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does OnKure Therapeutics compare to PureTech Health?

PureTech Health (NASDAQ:PRTC) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

PureTech Health has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market. Comparatively, OnKure Therapeutics has a beta of 0.12, meaning that its share price is 88% less volatile than the broader market.

OnKure Therapeutics has a consensus price target of $17.50, indicating a potential upside of 644.68%. Given OnKure Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe OnKure Therapeutics is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
OnKure Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

0.0% of PureTech Health shares are held by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are held by institutional investors. 5.3% of PureTech Health shares are held by company insiders. Comparatively, 2.2% of OnKure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, PureTech Health had 1 more articles in the media than OnKure Therapeutics. MarketBeat recorded 2 mentions for PureTech Health and 1 mentions for OnKure Therapeutics. OnKure Therapeutics' average media sentiment score of 1.79 beat PureTech Health's score of 0.00 indicating that OnKure Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
PureTech Health	Neutral
OnKure Therapeutics	Very Positive

OnKure Therapeutics has lower revenue, but higher earnings than PureTech Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A
OnKure Therapeutics	N/A	N/A	-$59.52M	-$3.50	N/A

PureTech Health's return on equity of 0.00% beat OnKure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	N/A	N/A	N/A
OnKure Therapeutics	N/A	-49.01%	-45.77%

Summary

PureTech Health and OnKure Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does OnKure Therapeutics compare to Rezolute?

Rezolute (NASDAQ:RZLT) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

Rezolute is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$77.59M	-$0.76	N/A
OnKure Therapeutics	N/A	N/A	-$59.52M	-$3.50	N/A

Rezolute presently has a consensus target price of $11.22, indicating a potential upside of 143.43%. OnKure Therapeutics has a consensus target price of $17.50, indicating a potential upside of 644.68%. Given OnKure Therapeutics' higher probable upside, analysts clearly believe OnKure Therapeutics is more favorable than Rezolute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
OnKure Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Rezolute has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market. Comparatively, OnKure Therapeutics has a beta of 0.12, meaning that its share price is 88% less volatile than the broader market.

83.0% of Rezolute shares are held by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are held by institutional investors. 14.8% of Rezolute shares are held by insiders. Comparatively, 2.2% of OnKure Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Rezolute had 3 more articles in the media than OnKure Therapeutics. MarketBeat recorded 4 mentions for Rezolute and 1 mentions for OnKure Therapeutics. OnKure Therapeutics' average media sentiment score of 1.79 beat Rezolute's score of 0.47 indicating that OnKure Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Rezolute	Neutral
OnKure Therapeutics	Very Positive

OnKure Therapeutics' return on equity of -49.01% beat Rezolute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-62.99%	-57.94%
OnKure Therapeutics	N/A	-49.01%	-45.77%

Summary

Rezolute and OnKure Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does OnKure Therapeutics compare to Arcturus Therapeutics?

OnKure Therapeutics (NASDAQ:OKUR) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability.

OnKure Therapeutics has a beta of 0.12, suggesting that its share price is 88% less volatile than the broader market. Comparatively, Arcturus Therapeutics has a beta of 2.48, suggesting that its share price is 148% more volatile than the broader market.

OnKure Therapeutics has higher earnings, but lower revenue than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OnKure Therapeutics	N/A	N/A	-$59.52M	-$3.50	N/A
Arcturus Therapeutics	$82.03M	4.17	-$65.78M	-$3.31	N/A

91.0% of OnKure Therapeutics shares are held by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are held by institutional investors. 2.2% of OnKure Therapeutics shares are held by company insiders. Comparatively, 17.8% of Arcturus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Arcturus Therapeutics had 4 more articles in the media than OnKure Therapeutics. MarketBeat recorded 5 mentions for Arcturus Therapeutics and 1 mentions for OnKure Therapeutics. OnKure Therapeutics' average media sentiment score of 1.79 beat Arcturus Therapeutics' score of 0.78 indicating that OnKure Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
OnKure Therapeutics	Very Positive
Arcturus Therapeutics	Positive

OnKure Therapeutics presently has a consensus price target of $17.50, indicating a potential upside of 644.68%. Arcturus Therapeutics has a consensus price target of $22.00, indicating a potential upside of 82.88%. Given OnKure Therapeutics' higher probable upside, analysts clearly believe OnKure Therapeutics is more favorable than Arcturus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.67

OnKure Therapeutics has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -317.62%. Arcturus Therapeutics' return on equity of -46.54% beat OnKure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-49.01%	-45.77%
Arcturus Therapeutics	-317.62%	-46.54%	-36.46%

Summary

Arcturus Therapeutics beats OnKure Therapeutics on 11 of the 15 factors compared between the two stocks.

How does OnKure Therapeutics compare to Eikon Therapeutics?

Eikon Therapeutics (NASDAQ:EIKN) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

Eikon Therapeutics' return on equity of 0.00% beat OnKure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eikon Therapeutics	N/A	N/A	N/A
OnKure Therapeutics	N/A	-49.01%	-45.77%

91.0% of OnKure Therapeutics shares are held by institutional investors. 2.2% of OnKure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Eikon Therapeutics is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eikon Therapeutics	N/A	N/A	-$324.25M	-$4.09	N/A
OnKure Therapeutics	N/A	N/A	-$59.52M	-$3.50	N/A

Eikon Therapeutics currently has a consensus target price of $25.00, suggesting a potential upside of 272.02%. OnKure Therapeutics has a consensus target price of $17.50, suggesting a potential upside of 644.68%. Given OnKure Therapeutics' higher probable upside, analysts plainly believe OnKure Therapeutics is more favorable than Eikon Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50
OnKure Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Eikon Therapeutics had 1 more articles in the media than OnKure Therapeutics. MarketBeat recorded 2 mentions for Eikon Therapeutics and 1 mentions for OnKure Therapeutics. OnKure Therapeutics' average media sentiment score of 1.79 beat Eikon Therapeutics' score of 1.43 indicating that OnKure Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Eikon Therapeutics	Positive
OnKure Therapeutics	Very Positive

Summary

Eikon Therapeutics and OnKure Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does OnKure Therapeutics compare to Aerovate Therapeutics?

OnKure Therapeutics (NASDAQ:OKUR) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership.

OnKure Therapeutics presently has a consensus price target of $17.50, indicating a potential upside of 644.68%. Given OnKure Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe OnKure Therapeutics is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, OnKure Therapeutics had 1 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 1 mentions for OnKure Therapeutics and 0 mentions for Aerovate Therapeutics. OnKure Therapeutics' average media sentiment score of 1.79 beat Aerovate Therapeutics' score of 0.00 indicating that OnKure Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
OnKure Therapeutics	Very Positive
Aerovate Therapeutics	Neutral

OnKure Therapeutics' return on equity of -49.01% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-49.01%	-45.77%
Aerovate Therapeutics	N/A	-90.19%	-77.47%

OnKure Therapeutics has a beta of 0.12, meaning that its stock price is 88% less volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market.

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OnKure Therapeutics	N/A	N/A	-$59.52M	-$3.50	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

91.0% of OnKure Therapeutics shares are held by institutional investors. 2.2% of OnKure Therapeutics shares are held by company insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

OnKure Therapeutics beats Aerovate Therapeutics on 9 of the 12 factors compared between the two stocks.

Get OnKure Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OKUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OKUR vs. The Competition

Export

Metric	OnKure Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$94.33M	$3.88B	$7.26B	$13.10B
Dividend Yield	N/A	3.65%	2.52%	22.89%
P/E Ratio	-0.67	13.21	275.54	25.58
Price / Sales	N/A	1,131.68	557.67	80.26
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	0.57	17.16	10.81	6.02
Net Income	-$59.52M	-$22.65M	$3.49B	$380.34M
7 Day Performance	-0.38%	-4.64%	-3.00%	-3.19%
1 Month Performance	-21.97%	-12.66%	-7.48%	-6.07%
1 Year Performance	-19.00%	8.08%	3.18%	-3.77%

OnKure Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OKUR OnKure Therapeutics	3.724 of 5 stars	$2.34 -0.4%	$17.50 +647.5%	-18.4%	$94.33M	N/A	N/A	45	Positive News
PRTC PureTech Health	0.0066 of 5 stars	$17.42 flat	N/A	N/A	$424.04M	$4.66M	N/A	100
RZLT Rezolute	3.2375 of 5 stars	$4.32 -0.2%	$11.22 +159.8%	-42.9%	$418.81M	N/A	N/A	58	Gap Up
ARCT Arcturus Therapeutics	2.8871 of 5 stars	$13.00 -11.3%	$22.43 +72.5%	-38.0%	$416.68M	$18.72M	N/A	111	Gap Down
EIKN Eikon Therapeutics	3.2984 of 5 stars	$7.51 -0.4%	$25.00 +232.9%	N/A	$408.40M	N/A	N/A	384	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OKUR) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OnKure Therapeutics (OKUR) Competitors

OKUR vs. PRTC, RZLT, ARCT, EIKN, and AVTE

How does OnKure Therapeutics compare to PureTech Health?

Summary

How does OnKure Therapeutics compare to Rezolute?

Summary

How does OnKure Therapeutics compare to Arcturus Therapeutics?

Summary

How does OnKure Therapeutics compare to Eikon Therapeutics?

Summary

How does OnKure Therapeutics compare to Aerovate Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKUR vs. The Competition

OnKure Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

OnKure Therapeutics (OKUR) Competitors

OKUR vs. PRTC, RZLT, ARCT, EIKN, and AVTE

How does OnKure Therapeutics compare to PureTech Health?

Which has more risk & volatility, PRTC or OKUR?

Do analysts prefer PRTC or OKUR?

Do institutionals and insiders believe in PRTC or OKUR?

Does the media prefer PRTC or OKUR?

Which has stronger earnings & valuation, PRTC or OKUR?

Is PRTC or OKUR more profitable?

Summary

How does OnKure Therapeutics compare to Rezolute?

Which has better valuation & earnings, RZLT or OKUR?

Do analysts prefer RZLT or OKUR?

Which has more volatility & risk, RZLT or OKUR?

Do institutionals & insiders believe in RZLT or OKUR?

Does the media prefer RZLT or OKUR?

Is RZLT or OKUR more profitable?

Summary

How does OnKure Therapeutics compare to Arcturus Therapeutics?

Which has more volatility and risk, OKUR or ARCT?

Which has stronger valuation & earnings, OKUR or ARCT?

Do insiders & institutionals hold more shares of OKUR or ARCT?

Does the media refer more to OKUR or ARCT?

Do analysts prefer OKUR or ARCT?

Is OKUR or ARCT more profitable?

Summary

How does OnKure Therapeutics compare to Eikon Therapeutics?

Is EIKN or OKUR more profitable?

Do institutionals & insiders have more ownership in EIKN or OKUR?

Which has preferable earnings & valuation, EIKN or OKUR?

Do analysts recommend EIKN or OKUR?

Does the media refer more to EIKN or OKUR?

Summary

How does OnKure Therapeutics compare to Aerovate Therapeutics?

Do analysts recommend OKUR or AVTE?

Does the media refer more to OKUR or AVTE?

Is OKUR or AVTE more profitable?

Which has more volatility and risk, OKUR or AVTE?

Which has stronger earnings & valuation, OKUR or AVTE?

Do institutionals & insiders hold more shares of OKUR or AVTE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKUR vs. The Competition

OnKure Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools